Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 16.67% | Add +0.3% | 3,343,817 | $12.07 | $40M | +11,085 | +$16M |
| OCUL - Ocular Therapeutix | 11.08% | Add +8.2% | 6,465,000 | $4.15 | $27M | +490,200 | +$3M |
| RYTM - Rhythm Pharmaceuticals | 8.20% | Add +123.8% | 810,000 | $24.50 | $20M | +448,000 | +$18M |
| TELA - Tela Bio | 7.17% | Add +23.9% | 2,036,551 | $8.52 | $17M | +393,184 | +$6M |
| CRNX - Crinetics Pharmaceuticals | 5.44% | Hold | 671,300 | $19.64 | $13M | — | — |
| CYTK - Cytokinetics | 5.26% | Reduce −13.1% | 263,000 | $48.45 | $13M | −39,500 | +$857K |
| Keros Therapeutics | 4.99% | Add +16.4% | 321,300 | $37.62 | $12M | +45,300 | +$4M |
| Protara Therapeutics | 3.30% | Add +0.9% | 2,708,067 | $2.95 | $8M | +23,900 | −$892K |
| CDXS - Codexis | 2.89% | Reduce −10.4% | 1,155,000 | $6.06 | $7M | −133,450 | −$6M |
| Tracon Pharmaceuticals | 2.89% | Add +1.6% | 4,190,000 | $1.67 | $7M | +64,678 | −$1M |
| Cutera | 2.78% | Hold | 147,700 | $45.60 | $7M | — | — |
| EWTX - Edgewise Therapeutics | 2.58% | Add +40.7% | 635,000 | $9.84 | $6M | +183,600 | +$3M |
| Mersana Therapeutics | 2.51% | Reduce −14.0% | 900,300 | $6.76 | $6M | −146,700 | +$1M |
| LRMR - Larimar Therapeutics | 2.20% | Add +78.1% | 1,661,784 | $3.20 | $5M | +728,970 | +$3M |
| ETON - Eton Pharmaceuticals | 2.19% | Add +2.4% | 2,521,000 | $2.10 | $5M | +58,500 | −$1M |
| Inhibrx | 2.17% | Reduce −50.4% | 292,700 | $17.95 | $5M | −297,300 | −$1M |
| Merus | 2.09% | Reduce −25.1% | 253,200 | $20.03 | $5M | −84,800 | −$3M |
| PCVX - Vaxcyte | 1.88% | Hold | 190,000 | $24.00 | $5M | — | — |
| XOMA - XOMA Del | 1.83% | Reduce −5.7% | 248,000 | $17.91 | $4M | −15,050 | −$1M |
| URGN - Urogen Pharma | 1.37% | Add +66.5% | 397,500 | $8.32 | $3M | +158,830 | +$1M |
| LQDA - Liquidia | 1.27% | Add +8.1% | 563,500 | $5.44 | $3M | +42,000 | +$791K |
| FDMT - 4D Molecular Therapeutics | 1.16% | Add +7.9% | 350,700 | $8.04 | $3M | +25,700 | +$551K |
| STXS - Stereotaxis | 1.16% | Reduce −25.9% | 1,556,800 | $1.80 | $3M | −543,171 | −$1M |
| Fortress Biotech | 1.07% | Reduce −7.6% | 2,999,000 | $0.8600 | $3M | −248,180 | −$148K |
| PRQR - Proqr Therapeutics | 0.96% | Add +13.7% | 3,115,000 | $0.7441 | $2M | +375,000 | +$187K |
| Graphite Bio | 0.76% | Add +25.5% | 577,250 | $3.17 | $2M | +117,250 | +$565K |
| Theseus Pharmaceuticals | 0.53% | Add +583.1% | 220,650 | $5.80 | $1M | +188,350 | +$1M |
| Impel Pharmaceuticals | 0.51% | Add +76.5% | 255,250 | $4.87 | $1M | +110,608 | −$105K |
| CATBUSD - Astria Therapeutics | 0.50% | New | 133,500 | $9.04 | $1M | +133,500 | +$1M |
| Modular Medical | 0.47% | Hold | 275,422 | $4.12 | $1M | — | — |
| Allakos | 0.39% | New | 153,500 | $6.12 | $939K | +153,500 | +$939K |
| Chimerix | 0.29% | Reduce −74.5% | 365,000 | $1.93 | $704K | −1,065,000 | −$2M |
| DERM - Journey Medicine | 0.26% | Add +5.5% | 259,293 | $2.46 | $638K | +13,560 | −$281K |
| Morphosys AG | 0.25% | New | 121,015 | $5.03 | $609K | +121,015 | +$609K |
| Edap Tms SA | 0.24% | New | 71,300 | $8.25 | $588K | +71,300 | +$588K |
| Neuropace | 0.18% | Add +29.1% | 116,324 | $3.75 | $436K | +26,224 | −$10K |
| Lumos Pharma | 0.17% | Add +116.4% | 46,576 | $8.85 | $412K | +25,056 | +$246K |
| Neoleukin Therapeutics | 0.15% | Reduce −5.7% | 575,000 | $0.6400 | $368K | −35,000 | −$260K |
| Optinose | 0.14% | Hold | 90,970 | $3.66 | $333K | — | — |
| MGTX - Meiragtx | 0.03% | New | 10,000 | $8.40 | $84K | +10,000 | +$84K |
| IDYA - Ideaya Biosciences | 0.01% | New | 1,500 | $14.67 | $22K | +1,500 | +$22K |
| Biolinerx | 0.01% | Hold | 16,667 | $0.9600 | $16K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals · CL A | 3.56% | Exit | 0 | $9.69 | $8M | −814,250 | −$8M |
| Reata Pharmaceuticals · CLASS A | 2.52% | Exit | 0 | $30.39 | $6M | −183,750 | −$6M |
| MASS - 908 Devices | 1.54% | Exit | 0 | $20.59 | $3M | −166,406 | −$3M |
| CLDX — | 1.09% | Exit | 0 | $26.96 | $2M | −90,000 | −$2M |
| Ginkgo Bioworks · CLASS A | 0.87% | Exit | 0 | $2.38 | $2M | −815,000 | −$2M |
| Verastem | 0.83% | Exit | 0 | $1.16 | $2M | −1,590,000 | −$2M |
| Hyperfine · CL A | 0.77% | Exit | 0 | $2.23 | $2M | −763,075 | −$2M |
| Macrogenics | 0.28% | Exit | 0 | $2.95 | $614K | −208,300 | −$614K |
| Forma Therapeutics | 0.18% | Exit | 0 | $6.88 | $404K | −58,700 | −$404K |
| Marinus Pharmaceuticals | 0.15% | Exit | 0 | $4.83 | $333K | −68,900 | −$333K |
| Avalo Therapeutics | 0.10% | Exit | 0 | $0.5000 | $225K | −450,000 | −$225K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2